Giralt Sergio, Logan Brent, Rizzo Douglas, Zhang Mei-Jie, Ballen Karen, Emmanouilides Christos, Nath Rajneesh, Parker Pablo, Porter David, Sandmaier Brenda, Waller Edmund K, Barker Juliet, Pavletic Steven, Weisdorf Daniel
The Nonmyeloablative Study Group, Center for International Blood and Marrow Transplant Research and the National Marrow Donor Program, Minneapolis, Minneapolis, USA.
Biol Blood Marrow Transplant. 2007 Jul;13(7):844-52. doi: 10.1016/j.bbmt.2007.03.011. Epub 2007 May 24.
To determine the long-term outcome of patients undergoing unrelated donor transplantation (URD) after a reduced intensity conditioning (RIC) regimen, we performed a retrospective analysis of the transplant outcomes of the first 5 years of RIC experience as reported to the National Marrow Donor Program (NMDP). Patients were included if they were older than 18 years and had undergone a URD transplant procured through the NMDP from January 1, 1996 until May 31, 2001, with an RIC regimen for a hematologic malignancy. The number of URDs performed using an RIC increased from 59 during 1996 to 1999, to 149 in the year 2000. RIC recipients were older (53 vs. 33 years) and had a higher likelihood of having advanced disease (81% vs. 51%) when compared to patients undergoing a myeloablative conditioning regimen during the same time period. The 5-year survival rate is 23% (95% confidence interval [CI]; 18, 28), whereas the 5 year incidence of progression/relapse is 43.4% (95% CI; 37,49). Prognostic factors for better overall survival on multivariate analysis were earlier disease stage, longer time to transplant from diagnosis, better HLA match, >or=90% performance score, and use of peripheral blood stem cells. This analysis demonstrates that long-term survival and disease control can be obtained with URD progenitor cell transplantation after RIC conditioning. However, only prospective trials will define the optimal role of this therapy in patients with hematologic malignancies. Therefore, URD transplantation with RIC should continue to be explored in the context of clinical trials.
为了确定接受非血缘供者移植(URD)并采用减低剂量预处理(RIC)方案的患者的长期预后,我们对向国家骨髓供者计划(NMDP)报告的RIC方案应用前5年的移植结果进行了回顾性分析。纳入标准为年龄大于18岁,于1996年1月1日至2001年5月31日期间通过NMDP接受URD移植,且因血液系统恶性肿瘤接受RIC方案预处理。采用RIC方案进行的URD移植数量从1996年至1999年的59例增加到2000年的149例。与同期接受清髓性预处理方案的患者相比,RIC方案的接受者年龄更大(53岁对33岁),且疾病进展期的可能性更高(81%对51%)。5年生存率为23%(95%可信区间[CI]:18,28),而5年疾病进展/复发率为43.4%(95%CI:37,49)。多因素分析显示,总生存较好的预后因素包括疾病分期较早、从诊断到移植的时间较长、HLA匹配较好、体能状态评分≥90%以及使用外周血干细胞。该分析表明,RIC预处理后进行URD祖细胞移植可获得长期生存和疾病控制。然而,只有前瞻性试验才能确定该疗法在血液系统恶性肿瘤患者中的最佳作用。因此,应在临床试验背景下继续探索RIC方案的URD移植。